U1DA — MOLOGEN Lifescience AG Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.13 | ||
| Price to Tang. Book | 1.13 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.84% | ||
| Return on Equity | -4.64% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 0.1 | 0.02 | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MOLOGEN Lifescience AG, formerly Finchain Capital Partners AG, is a Germany-based company. The Company is in the development, manufacturing, acquisition, licensing, distribution, and marketing of products, processes, and services in the fields of life sciences, biotechnology, medical technology, healthcare, and pharmaceuticals. In addition, the Company is engaged in the research, development, production, and commercialization of biotechnological technologies and active ingredients, including but not limited to nanotechnology and microbiological systems, as well as activated vesicle technologies and their application in dietary supplements, cosmetic products, medical preparations, and therapeutic procedures. It operates pharmaceutical facilities, in particular mail-order pharmacies, manufacturing facilities, cleanroom laboratories, and other laboratory and diagnostic facilities.
Directors
- Last Annual
- December 31st, 2021
- Last Interim
- June 30th, 2024
- Incorporated
- March 27th, 2015
- Public Since
- August 18th, 2016
- Sector
- Investment Banking & Investment Services
- Industry
- Financials
- Exchange
- Frankfurt Stock Exchange
- Shares in Issue
- 1,378,750
- Address
- Johnsallee 30, HAMBURG, 20148
- Web
- https://finchaincapital.com/
- Phone
- +49 4042236668
- Auditors
- Wirtschaftsprüfung GmbH & Co KG
Upcoming Events for U1DA
Similar to U1DA
Abaxx Technologies
Frankfurt Stock Exchange
Adcapital AG
Frankfurt Stock Exchange
Berliner Effektengesellschaft AG
Frankfurt Stock Exchange
Camerit AG
Frankfurt Stock Exchange
capsensixx AG
Frankfurt Stock Exchange
FAQ
As of Today at 02:38 UTC, shares in MOLOGEN Lifescience AG are trading at €3.00. This share price information is delayed by 15 minutes.
Shares in MOLOGEN Lifescience AG last closed at €3.00 and the price had moved by +106.9% over the past 365 days. In terms of relative price strength the MOLOGEN Lifescience AG share price has outperformed the FTSE Global All Cap Index by +80.18% over the past year.
There is no consensus recommendation for this security.
Find out moreMOLOGEN Lifescience AG does not currently pay a dividend.
MOLOGEN Lifescience AG does not currently pay a dividend.
MOLOGEN Lifescience AG does not currently pay a dividend.
To buy shares in MOLOGEN Lifescience AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €3.00, shares in MOLOGEN Lifescience AG had a market capitalisation of €4.14m.
Here are the trading details for MOLOGEN Lifescience AG:
- Country of listing: Germany
- Exchange: FRA
- Ticker Symbol: U1DA
Based on an overall assessment of its quality, value and momentum MOLOGEN Lifescience AG is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MOLOGEN Lifescience AG. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +25.31%.
As of the last closing price of €3.00, shares in MOLOGEN Lifescience AG were trading +16.75% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The MOLOGEN Lifescience AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €3.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
MOLOGEN Lifescience AG's management team is headed by:
- Martin Uzik - CSU
- Wolfgang Siewering - VSU
- Norbert Schmidt - MGB
- Christian Schmitz - MGB
- Uwe Heller - SUB